CBDN Stock Overview
CBD Global Sciences Inc. engages in cannabidiol (CBD) farming, processing, and product manufacturing business.
Price History & Performance
|Historical stock prices|
|Current Share Price||CA$0.19|
|52 Week High||CA$0.65|
|52 Week Low||CA$0.13|
|1 Month Change||-11.63%|
|3 Month Change||-24.00%|
|1 Year Change||-13.64%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-39.68%|
Recent News & Updates
|CBDN||CA Pharmaceuticals||CA Market|
Return vs Industry: CBDN exceeded the Canadian Pharmaceuticals industry which returned -53.3% over the past year.
Return vs Market: CBDN underperformed the Canadian Market which returned 19.1% over the past year.
|CBDN Average Weekly Movement||32.9%|
|Pharmaceuticals Industry Average Movement||11.7%|
|Market Average Movement||9.7%|
|10% most volatile stocks in CA Market||17.6%|
|10% least volatile stocks in CA Market||3.7%|
Stable Share Price: CBDN is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 33% a week.
Volatility Over Time: CBDN's weekly volatility has increased from 26% to 33% over the past year.
About the Company
CBD Global Sciences Inc. engages in cannabidiol (CBD) farming, processing, and product manufacturing business. It offers provides biomass, CBD oil, and CBD oil products under the Aethics, CannaOil, and Strasburg Pharms brand names. The company was incorporated in 2018 and is headquartered in Lakewood, Colorado.
CBD Global Sciences Fundamentals Summary
|CBDN fundamental statistics|
Is CBDN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CBDN income statement (TTM)|
|Cost of Revenue||US$3.77m|
Last Reported Earnings
Sep 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.11|
|Net Profit Margin||6,891.16%|
How did CBDN perform over the long term?See historical performance and comparison
Is CBD Global Sciences undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether CBD Global Sciences is trading at an attractive price based on the cash flow it is expected to produce in the future. But as CBD Global Sciences has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
How is CBD Global Sciences forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as CBD Global Sciences has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has CBD Global Sciences performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: CBDN is currently unprofitable.
Growing Profit Margin: CBDN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CBDN's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare CBDN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CBDN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (30.8%).
Return on Equity
High ROE: CBDN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
How is CBD Global Sciences's financial position?
Financial Position Analysis
Short Term Liabilities: CBDN has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: CBDN has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: CBDN has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: CBDN's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: CBDN has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: CBDN has less than a year of cash runway if free cash flow continues to grow at historical rates of 26.4% each year.
What is CBD Global Sciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate CBDN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate CBDN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if CBDN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if CBDN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of CBDN's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
How experienced are the management team and are they aligned to shareholders interests?
Brad Wyatt (52 yo)
Mr. Brad Wyatt is a Co-Founder of CBD Global Sciences Inc. and also serves as its Chief Executive Officer, President and Director. Mr. Wyatt served as Chief Executive Officer, President, and Executive Dire...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 16.4%.
CBD Global Sciences Inc.'s employee growth, exchange listings and data sources
- Name: CBD Global Sciences Inc.
- Ticker: CBDN
- Exchange: CNSX
- Founded: 2018
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CA$7.582m
- Shares outstanding: 39.90m
- Website: https://www.cbdglobalsciences.com
- CBD Global Sciences Inc.
- 225 Union Boulevard
- Suite 350
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/01/17 23:18|
|End of Day Share Price||2022/01/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.